Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AETX-R302
- Development stage
- Preclinical
- Lead developer
- Aethon Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AETX-R302 is a preclinical monoclonal antibody developed by Aethon Therapeutics using its proprietary HapImmune™ platform. It is designed to target KRAS G12C-mutant cancers in a combination strategy with the covalent KRAS G12C inhibitor divarasib. The antibody specifically recognizes a unique neoantigen (hapten-pMHC) formed when divarasib covalently modifies the KRAS G12C protein, which is subsequently processed and presented on the cell surface by MHC molecules. AETX-R302 demonstrates high-affinity (KD ranging between 0.78 and 2.75 nM) and pan-HLA recognition across HLA-A*02 (A2 supertype) and HLA-A*03/A*11 (A3 supertype) alleles. By targeting these drug-induced neoantigens, AETX-R302 aims to direct the immune system to selectively eliminate cancer cells, including drug-resistant "persister" cells that may survive initial inhibitor treatment.
- Other names
- anti-diva-pMHC antibodydivarasib-modified KRAS G12C peptide-MHC antibody
02
Targets
Divarasib-KRAS G12C-pMHC (Divarasib-modified KRAS G12C peptide–MHC class I complex)
Beyond the preview
Go deeper on AETX-R302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AETX-R302.